Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Reparixin (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Dompe Spa
- 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
- 11 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 13 Dec 2014 Status changed from active, no longer recruiting to completed, based on the information in the abstract presented at the 37th Annual San Antonio Breast Cancer Symposium.